FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308485466> ?p ?o ?g. }

• W4308485466 abstract "Abstract Studies reporting vaccine effectiveness against COVID-19 outcomes concentrate mainly on estimates of one single type of vaccine and variant, seldom considering waning effects. We aimed to estimate the effectiveness of the overall COVID-19 vaccination programme implemented in the Apulia region of Italy at preventing SARS-CoV-2 infections, COVID-19-related hospital admissions and deaths during alpha and delta variant dominant periods. We conducted a retrospective cohort study using electronic health records of persons 16 years and older resident in the Apulia region, assessing the effectiveness of the combined use of BNT162b2, mRNA-1273, ChAdOx1-S and Ad26.COV2.S vaccines against confirmed COVID-19 infections, hospitalisations and deaths, for fully and partially vaccinated persons as well as by time since vaccination and variants. Cox regression models yielding hazard ratios were used to calculate the overall vaccination programme effectiveness. From 1 January to 1 December 2021, we included 3,530,967 eligible persons in the cohort, of whom 2,770,299 were fully vaccinated and 158,313 were COVID-19 positive at the end of the study period. The effectiveness of the programme over the entire study period for fully vaccinated persons against COVID-19 infection, hospitalisation and death were 87.69% (CI95% 87.73–88.18), 94.08% (93.58–94.54) and 95.95% (CI95% 95.26–96.54), respectively. The effectiveness against COVID-19 infection of fully vaccinated subjects during the alpha and delta period was respectively 88.20% (CI95% 87.60–99.78) and 59.31% (CI95% 57.91–60.67), against hospitalisation 93.89% (CI95% 92.67–94.90) and 88.32% (CI95% 86.50–89.90) and against death 93.83% (CI95% 91.65–95.45) and 85.91 (CI95% 79.98–90.09). The waning effects of the programme regarding COVID-19 infection during the delta period were stronger than for alpha, with 75.85% (CI95% 74.38–77.24) effectiveness after 1–2 months and 8.35% (CI95% 3.45–13.01) after 5–6 months after full vaccination. The effectiveness against hospitalisation and death during the delta period waned rapidly and at 7–8-months after the full vaccination respectively decreased to 27.67% (CI95% 7.48–43.45) and 48.47 (CI95% 53.97–34.82). Our study suggests that the COVID-19 vaccination program in Apulia was strongly protective against COVID-19 infection, hospitalisation, and death due to alpha as well as delta variants, although its effectiveness is reduced over time." @default.
• W4308485466 created "2022-11-12" @default.
• W4308485466 creator A5019634904 @default.
• W4308485466 creator A5035132828 @default.
• W4308485466 creator A5036161367 @default.
• W4308485466 creator A5044579578 @default.
• W4308485466 creator A5053853585 @default.
• W4308485466 creator A5070101498 @default.
• W4308485466 creator A5074308450 @default.
• W4308485466 creator A5075074323 @default.
• W4308485466 creator A5085993448 @default.
• W4308485466 creator A5088323200 @default.
• W4308485466 date "2022-11-03" @default.
• W4308485466 modified "2023-10-17" @default.
• W4308485466 title "Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study" @default.
• W4308485466 cites W2098418331 @default.
• W4308485466 cites W2149803415 @default.
• W4308485466 cites W3111255098 @default.
• W4308485466 cites W3111590711 @default.
• W4308485466 cites W3153508314 @default.
• W4308485466 cites W3158123254 @default.
• W4308485466 cites W3158276912 @default.
• W4308485466 cites W3159994714 @default.
• W4308485466 cites W3162622073 @default.
• W4308485466 cites W3177903130 @default.
• W4308485466 cites W3182094313 @default.
• W4308485466 cites W3183560460 @default.
• W4308485466 cites W3184226105 @default.
• W4308485466 cites W3187192250 @default.
• W4308485466 cites W3193938173 @default.
• W4308485466 cites W3201105003 @default.
• W4308485466 cites W3202826390 @default.
• W4308485466 cites W3205549161 @default.
• W4308485466 cites W3206181818 @default.
• W4308485466 cites W3213370807 @default.
• W4308485466 cites W4200560177 @default.
• W4308485466 cites W4205405695 @default.
• W4308485466 cites W4205483821 @default.
• W4308485466 cites W4205810842 @default.
• W4308485466 cites W4206424900 @default.
• W4308485466 cites W4211029192 @default.
• W4308485466 cites W4211200665 @default.
• W4308485466 cites W4226114338 @default.
• W4308485466 cites W4226192094 @default.
• W4308485466 cites W4226321964 @default.
• W4308485466 cites W4226343533 @default.
• W4308485466 cites W4226376477 @default.
• W4308485466 doi "https://doi.org/10.1038/s41598-022-23235-4" @default.
• W4308485466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36329239" @default.
• W4308485466 hasPublicationYear "2022" @default.
• W4308485466 type Work @default.
• W4308485466 citedByCount "3" @default.
• W4308485466 countsByYear W43084854662022 @default.
• W4308485466 countsByYear W43084854662023 @default.
• W4308485466 crossrefType "journal-article" @default.
• W4308485466 hasAuthorship W4308485466A5019634904 @default.
• W4308485466 hasAuthorship W4308485466A5035132828 @default.
• W4308485466 hasAuthorship W4308485466A5036161367 @default.
• W4308485466 hasAuthorship W4308485466A5044579578 @default.
• W4308485466 hasAuthorship W4308485466A5053853585 @default.
• W4308485466 hasAuthorship W4308485466A5070101498 @default.
• W4308485466 hasAuthorship W4308485466A5074308450 @default.
• W4308485466 hasAuthorship W4308485466A5075074323 @default.
• W4308485466 hasAuthorship W4308485466A5085993448 @default.
• W4308485466 hasAuthorship W4308485466A5088323200 @default.
• W4308485466 hasBestOaLocation W43084854661 @default.
• W4308485466 hasConcept C126322002 @default.
• W4308485466 hasConcept C144024400 @default.
• W4308485466 hasConcept C149923435 @default.
• W4308485466 hasConcept C159047783 @default.
• W4308485466 hasConcept C167135981 @default.
• W4308485466 hasConcept C187212893 @default.
• W4308485466 hasConcept C201903717 @default.
• W4308485466 hasConcept C207103383 @default.
• W4308485466 hasConcept C22070199 @default.
• W4308485466 hasConcept C2779134260 @default.
• W4308485466 hasConcept C3007834351 @default.
• W4308485466 hasConcept C3008058167 @default.
• W4308485466 hasConcept C44249647 @default.
• W4308485466 hasConcept C50382708 @default.
• W4308485466 hasConcept C524204448 @default.
• W4308485466 hasConcept C71924100 @default.
• W4308485466 hasConcept C72563966 @default.
• W4308485466 hasConceptScore W4308485466C126322002 @default.
• W4308485466 hasConceptScore W4308485466C144024400 @default.
• W4308485466 hasConceptScore W4308485466C149923435 @default.
• W4308485466 hasConceptScore W4308485466C159047783 @default.
• W4308485466 hasConceptScore W4308485466C167135981 @default.
• W4308485466 hasConceptScore W4308485466C187212893 @default.
• W4308485466 hasConceptScore W4308485466C201903717 @default.
• W4308485466 hasConceptScore W4308485466C207103383 @default.
• W4308485466 hasConceptScore W4308485466C22070199 @default.
• W4308485466 hasConceptScore W4308485466C2779134260 @default.
• W4308485466 hasConceptScore W4308485466C3007834351 @default.
• W4308485466 hasConceptScore W4308485466C3008058167 @default.
• W4308485466 hasConceptScore W4308485466C44249647 @default.
• W4308485466 hasConceptScore W4308485466C50382708 @default.
• W4308485466 hasConceptScore W4308485466C524204448 @default.
• W4308485466 hasConceptScore W4308485466C71924100 @default.
• W4308485466 hasConceptScore W4308485466C72563966 @default.

• next